Novo Nordisk: This Options Strategy Was Profitable Even With The Stock Down

I first wrote about Novo Nordisk ( NVO ) in mid-May, when the stock was around $65. My base-case Fair Value estimate was $83, derived from three sources: a comparison with peers, a DDM (Discounted Dividend Model) and a DCF (Discounted Analyst's Disclosure:I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). ...